Latest Articles
Figure 4. Kaplan-Meier survival curves for OS stratified by tumor... - researchgate.net
Figure 4. Kaplan-Meier survival curves for OS stratified by tumor... researchgate.net
Published: Aug. 28, 2025, 11:27 p.m.
Acrivon's Cancer Drug Pipeline Advances with Tumor Response in Endometrial Cancer Trials - Stock Titan
Acrivon's Cancer Drug Pipeline Advances with Tumor Response in Endometrial Cancer Trials Stock Titan
Published: Aug. 13, 2025, 8:15 p.m.
Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight - The Malaysian Reserve
Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight The Malaysian Reserve
Published: Aug. 12, 2025, 10:20 p.m.
Triple Threat: Co-occurrence of Serous Borderline Ovarian Tumor, Endometrial Adenocarcinoma, and Low-Grade Appendiceal Mucinous Neoplasms With Pseudomyxoma Peritonei in a Single Patient - Cureus
Triple Threat: Co-occurrence of Serous Borderline Ovarian Tumor, Endometrial Adenocarcinoma, and Low-Grade Appendiceal Mucinous Neoplasms With Pseudomyxoma Peritonei in a Single Patient Cureus
Published: July 20, 2025, 7:43 a.m.
ASCO Reading Room | More Precise Treatments for Rare Uterine Tumors - MedPage Today
ASCO Reading Room | More Precise Treatments for Rare Uterine Tumors MedPage Today
Published: July 9, 2025, 3:13 p.m.
Chennai pvt hospital relieves woman with 2 tumorous wombs of pain - dtnext
Chennai pvt hospital relieves woman with 2 tumorous wombs of pain dtnext
Published: June 26, 2025, 1:20 a.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace
Published: June 2, 2025, 11:48 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire
Published: June 2, 2025, 6:32 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo Finance
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo Finance
Published: June 2, 2025, 6:30 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo
Published: June 2, 2025, 6:30 p.m.
Link copied to clipboard!